Global Musculoskeletal Disorders Drugs Market Report 2017; New Report Launched
The product approvals of new musculoskeletal drugs by regulatory bodies is a significant positive trend being witnessed by the market in recent years. For instance, in April 2017, BioMarin received FDA approval for its Brineura (cerliponase alfa) drug that is used for the treatment of late infantile neuronal ceroid lipofuscinosis type 2. In May 2017, Sanofi received FDA approval for its Kevzara drug that is used in the treatment of active rheumatoid arthritis.
View full press release